" class="no-js "lang="en-US"> Diwakar Turaga - Medtech Alert
Thursday, October 09, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Diwakar Turaga

Diwakar Turaga

About Diwakar Turaga

My primary career objective is to combine clinical work in pediatric cardiac critical care with research in cardiac regenerative medicine.

Clinical Interests:

Single ventricle physiology, ventricular assist devices

Related Story

Cardiovascular

 New Understanding of Congenital Heart Disease Progression Opens Door to Improved Treatment Options | Pharmtech Focus

New Understanding of Congenital Heart Disease Progression Opens Door to Improved Treatment Options

June 23 2022

A team of investigators from Texas Heart Institute, Texas Children’s Hospital and Baylor College of Medicine uncovered […]